ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA – Get Free Report) saw a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 187,900 shares, an increase of 323.2% from the February 28th total of 44,400 shares. Based on an average daily volume of 830,400 shares, the short-interest ratio is currently 0.2 days. Approximately 7.5% of the company’s stock are sold short.
Institutional Trading of ZyVersa Therapeutics
An institutional investor recently bought a new position in ZyVersa Therapeutics stock. Virtu Financial LLC bought a new stake in shares of ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 25,259 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned about 1.08% of ZyVersa Therapeutics at the end of the most recent reporting period. 3.91% of the stock is currently owned by hedge funds and other institutional investors.
ZyVersa Therapeutics Stock Performance
ZyVersa Therapeutics stock opened at $0.73 on Thursday. ZyVersa Therapeutics has a fifty-two week low of $0.69 and a fifty-two week high of $8.40. The firm’s 50-day simple moving average is $1.13 and its 200 day simple moving average is $1.48.
About ZyVersa Therapeutics
ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.
Read More
- Five stocks we like better than ZyVersa Therapeutics
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Energy Transfer: Powering Data With Dividends and Diversification
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Qualcomm Stock Is Coiling for a Breakout
- What Is WallStreetBets and What Stocks Are They Targeting?
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for ZyVersa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZyVersa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
